Tokyo, April 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061238) titled 'Exploratory study on the safety of yogurt ingestion and glycemic variabili... Read More
Tokyo, April 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061237) titled 'A two-center prospective observational study of treatment continuity with ... Read More
Tokyo, April 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061236) titled 'Multicenter repeated point prevalence study of the recognition gap of deli... Read More
Tokyo, April 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061235) titled 'Inter-facility Variation in Palliative Sedation Practices: A Multicenter P... Read More
Tokyo, April 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061234) titled 'Validation of the Criterion-Related Validity of "A Tool for Clinical Rehab... Read More
Tokyo, April 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061230) titled 'Optimal Cut-Points for Orthostatic Hypotension Using a Sit-up Test: A Mult... Read More
Tokyo, April 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061222) titled 'Effects of combined manual pressure to the posterior lower leg and active ... Read More
Tokyo, April 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061195) titled 'Development of a Simplified Goal-Setting Diary for Long-Term Care Preventi... Read More
Singapore, April 12 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More
Singapore, April 12 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More